489 related articles for article (PubMed ID: 18052762)
21. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
[TBL] [Abstract][Full Text] [Related]
22. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
23. Oral almotriptan: practical uses in the acute treatment of migraine.
Dowson AJ
Expert Rev Neurother; 2004 May; 4(3):339-48. PubMed ID: 15853532
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
25. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
Kelman L; Von Seggern RL
Am J Ther; 2006; 13(5):411-7. PubMed ID: 16988536
[TBL] [Abstract][Full Text] [Related]
26. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
27. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management.
Goadsby PJ; Dodick DW; Ferrari MD; McCrory DC; Williams P
Acta Neurol Scand; 2004 Sep; 110(3):137-43. PubMed ID: 15285768
[TBL] [Abstract][Full Text] [Related]
28. Clinical profile and practice experience of almotriptan.
Gendolla A
Cephalalgia; 2004; 24 Suppl 2():16-23. PubMed ID: 15595990
[TBL] [Abstract][Full Text] [Related]
29. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
30. Triptan nonresponder studies: implications for clinical practice.
Dodick DW
Headache; 2005 Feb; 45(2):156-62. PubMed ID: 15705122
[TBL] [Abstract][Full Text] [Related]
31. Clinical benefits of early triptan therapy for migraine.
Láinez M
Cephalalgia; 2004; 24 Suppl 2():24-30. PubMed ID: 15595991
[TBL] [Abstract][Full Text] [Related]
32. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
33. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
Diener HC
Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
[TBL] [Abstract][Full Text] [Related]
34. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
Mannix LK; Adelman JU; Goldfarb SD; Von S; Kozma CM
Am J Manag Care; 2002 Feb; 8(3 Suppl):S94-101. PubMed ID: 11859910
[TBL] [Abstract][Full Text] [Related]
35. Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.
Dahlöf CG
Cephalalgia; 2006 Feb; 26(2):98-106. PubMed ID: 16426262
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of almotriptan in controlled clinical trials.
Mathew NT
Eur Neurol; 2005; 53 Suppl 1():29-33. PubMed ID: 15920335
[TBL] [Abstract][Full Text] [Related]
37. Migraine: diagnosis, management, and new treatment options.
Gallagher RM; Cutrer FM
Am J Manag Care; 2002 Feb; 8(3 Suppl):S58-73. PubMed ID: 11859906
[TBL] [Abstract][Full Text] [Related]
38. [Economic evaluation of acute migraine attack treatment with triptans in Spain].
Gracia-Naya M; Rejas Gutiérrez J; Latorre Jiménez A; González Garcia P
Neurologia; 2005 Apr; 20(3):121-32. PubMed ID: 15815947
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic evaluation of almotriptan for the treatment of migraines.
Negro A; Lionetto L; D'Alonzo L; Casolla B; Marsibilio F; Vignaroli G; Simmaco M; Martelletti P
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):637-44. PubMed ID: 23570251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
